[1] SINGH D, AGUSTI A, ANZUETO A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease: the GOLD science committee report 2019[J].Eur Respir J,2019, 53(5):1900164.
[2] WANG C, XU J, YANG L, et al. Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health [CPH] study): a national cross-sectional study [J].Lancet,2018, 391(10131): 1706-1717.
[3] LOZANO R, NAGHAVI M, FOREMAN K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010 [J].Lancet,2012, 380(9859): 2095-2128.
[4] CORRADO A, ROSSI A. How far is real life from COPD therapy guidelines? An Italian observational study [J].Respir Med,2012, 106(7): 989-997.
[5] RIARIO-SFORZA G, INCORVAIA C, PRAVETTONI C, et al. Guidelines versus clinical practice in the treatment of COPD: a reappraisal [J].Eur Respir J,2006, 27(3): 656.
[6] BAHA A, KOKTURK N. Physician's attitude against COPD guidelines and the choice of first-line treatment for COPD [J].Respir Med,2021, 176:106273.
[7] 中华医学会呼吸病学分会慢性阻塞性肺疾病学组, 中国医师协会呼吸医师分会慢性阻塞性肺疾病工作委员会. 慢性阻塞性肺疾病诊治指南(2021年修订版) [J].中华结核和呼吸杂志, 2021, 44(3): 170-205.
[8] YANG I, CLARKE M, SIM E, et al. Inhaled corticosteroids for stable chronic obstructive pulmonary disease [J].Cochrane Database Syst Rev,2012(7): CD002991.
[9] BEKKAT-BERKANI R, WILKINSON T, BUCHY P, et al. Seasonal influenza vaccination in patients with COPD: a systematic literature review [J].BMC Pulm Med,2017, 17(1): 1-15.
[10] TOMCZYK S, BENNETT N, STOECKER C, et al. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged≥65 years: recommendations of the Advisory Committee on Immunization Practices (ACIP) [J]. MMWR Morb Mortal Wkly Rep,2014, 63(37): 822-825.
[11] ZENG Y, CAI S, CHEN Y, et al. Current status of the treatment of COPD in China: a multicenter prospective observational study[J].Int J Chron Obstruct Pulmon Dis,2020, 15: 3227-3237.
[12] MALTAIS F, BJERMER L, KERWIN E M, et al. Efficacy of umeclidinium/vilanterol versus umeclidinium and salmeterol monotherapies in symptomatic patients with COPD not receiving inhaled corticosteroids: the EMAX randomised trial [J].Respir Res,2019, 20(1): 238.
[13] CHENA W, DUAN J,ZHOU A, et al. Real-world effectiveness of inhalation therapy among patients with symptomatic COPD in China: a multicenter prospective study [J].Front Pharmacol,2021, 12: 753653.
[14] LIU C, CHENG W, ZENG Y, et al. Different Characteristics of ex-smokers and current smokers with COPD: a cross-sectional study in China [J].Int J Chron Obstruct Pulmon Dis,2020, 15: 1613-1619.
[15] SCHOEFER Y, SCHABERG T, RASPE H, et al. Determinants of influenza and pneumococcal vaccination in patients with chronic lung diseases [J].J Infect,2007, 55(4): 347-352.
[16] HSU D, NORTH C, BRODE S, et al. Identification of barriers to influenza vaccination in patients with chronic obstructive pulmonary disease: analysis of the 2012 behavioral risk factors surveillance system [J].Chronic Obstr Pulm Dis Actions,2016, 3(3): 620-627.
[17] CARREÑO-IBáÑEZ L, ESTEBAN-VASALLO M. Coverage of and factors associated with pneumococcal vaccination in chronic obstructive pulmonary disease [J].Int J Tuberc Lung Dis,2015, 19(6): 735-741.
[18] FAN J, CONG S, WANG N, et al. Influenza vaccination rate and its association with chronic diseases in China: Results of a national cross-sectional study [J].Vaccine,2020, 38(11): 2503-2511. |
2022, Vol. 39 
